01 — Opening Hook
The Optimistic Acquisitor’s Dilemma
Imagine a hospital chain that walks into earnings and says: “We’re growing at 17.5%, margins are expanding, occupancy is holding steady at 67%, and we just acquired three hospitals in the last six months.” Then ask them about integration pain, debt servicing costs climbing faster than profit, and when all this brownfield expansion becomes accretive. Watch them squirm. Because sometimes, growth begets complexity. And complexity begets uncomfortable investor questions about capital allocation.
Fortis Healthcare posted Q3 FY26 consolidated revenue of ₹2,265 crores (up 17.5% YoY), operating EBITDA of ₹505 crores (margin 22.3%), and blended PAT of ₹197 crores. Good. But net debt climbed to ₹2,547 crores. Gleneagles is bleeding (4% negative growth in 9M, clinician attrition, leadership churn). New acquisitions (People Tree Bangalore for ₹430 Cr, Jalandhar, Greater Noida) are dragging occupancy metrics. And management promised 20% topline growth for FY27 with “gradual margin improvement”—which means nothing is promised. Read on, because this gets interesting in a very-regulatory-nightmare, very-execution-dependent kind of way.
Read on: Management is chasing scale aggressively, but every acquisition needs 3-4 years to ramp. ARPOB grew 4.5%, EBITDA margins are sticky at 22-23%, and leverage is climbing. The question isn’t “can we grow”—it’s “can we grow profitably at this capex burn rate”?
02 — At a Glance
The Quarterly Numbers Play
Q3 Consolidated Revenue
₹2,265 Cr
+17.5% YoY. Hospital: 19.4%. Diagnostics: 7.3%. Growth is real, but uneven across segments.
Q3 Operating EBITDA
₹505 Cr
+34.8% YoY. Margin: 22.3% vs 19.4% last year. Hospital margin: 21.7% (up from 20%). Impressive leverage.
Q3 Reported PAT
₹197 Cr
Flat YoY (vs ₹250 Cr). Labour code exceptional loss: ₹55 Cr. Without that: ₹252 Cr. Math game on taxation & one-offs.
Hospital Occupancy
67%
Steady QoQ. But occupied beds up 14% (3,189 vs 2,790). New facilities dragging average occupancy.
ARPOB (₹ Cr/annum)
₹2.56
+4.5% YoY. Robotic surgeries up 52%. Case mix driving ARPOB, not price hikes. Target: 4-5% annual growth.
Net Debt / EBITDA
1.24x
Up from 0.8x (Mar ’25). Debt: ₹3,195 Cr. Acquisitions funded debt; margin climb offset cost.
The Brutal Truth: Growth is there. Margins are expanding. But leverage is tightening faster than profit growth can handle. Each ₹430 Cr acquisition adds ₹200-250 Cr debt, requires 3+ years to ramp, and drags returns on capital lower until consolidated at steady-state 20%+ EBITDA.
03 — Management’s Key Commentary
What They Said. What They Really Meant.
Dr. Ashutosh Raghuvanshi (MD & CEO): “Our business performance in Q3 has been good, considering seasonal impact of festivals in some of our key geographies.”
😏 Translation: We knew demand would be lumpy. Festival season is a known headwind. Doesn’t mean operations are hard.
Vivek Goyal (CFO): “On the Gleneagles O&M integration: we have earned ₹5 crores in fee. There is clinician attrition, management team changes. Results will show from next financial year onward.”
🤷 Translation: We took over in July. So far it’s bleeding in every facility. Chennai: execution problems. Hyderabad: clinician attrition. Bangalore: two hospitals, one okay, one needs work. But we promise the management overhaul will fix it (after it destroys margins for 12 months).
Dr. Raghuvanshi: “The People Tree acquisition will be expanded from 125 beds to 300 beds over 3-4 years. It’s sub-optimal now but we’ll bring it to Fortis standards.”
💣 Translation: We paid ₹430 Cr for a half-built, sub-40% occupancy hospital. It needs ₹200+ Cr more in capex. In 4 years it’ll be a 25% EBITDA facility (we hope). That’s a *really* long runway for returns on that much capital.
Vivek Goyal: “13 of our facilities report EBITDA margins above 20%, contributing 77% of hospital revenue. Last year: 10 facilities at 73%.”
✨ Translation: We’re consolidating. Flagship hospitals are fortress-profitable. Everything else is a ramp or a drag. The tail (low-margin units) isn’t getting cut, but will get surgical fixes eventually.
Vivek Goyal (on FY27 outlook): “You will continue to see the growth trajectory for at least 2 years. Brownfield expansion, especially FMRI expansion, will support margins.”
📊 Translation: We can deliver 15-20% topline growth. But specific margin targets? We’re not giving them. Capex will be high. Debt won’t fall. And if inflation hits, we’re squeezing from both ends.
Vivek Goyal (on IHH equity infusion): “IHH has expressed willingness to increase stake post open offer. Cooling period ends May. Equity infusion in 3-6 months likely. Preferential allotment ~5%.”
🎯 Translation: Fortis is drowning in debt. IHH is stepping in. Parent company will inject ₹500-800 Cr likely (5% = ~₹3,000 Cr market cap = ₹150 Cr). That capital either pays down debt or funds *more* acquisition. Leverage doesn’t resolve unless IHH writes ₹1,500+ Cr check.
04 — Numbers Decoded
The Financial Scorecard
